NO20064811L - 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase - Google Patents

4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase

Info

Publication number
NO20064811L
NO20064811L NO20064811A NO20064811A NO20064811L NO 20064811 L NO20064811 L NO 20064811L NO 20064811 A NO20064811 A NO 20064811A NO 20064811 A NO20064811 A NO 20064811A NO 20064811 L NO20064811 L NO 20064811L
Authority
NO
Norway
Prior art keywords
inhibitor
compound
thiophen
piperidin
aminomethyl
Prior art date
Application number
NO20064811A
Other languages
English (en)
Inventor
Mark Czekaj
Adam W Sledeski
Zhongli Gao
Larry Davis
Julian Levell
El-Bdaoui Haddad
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20064811L publication Critical patent/NO20064811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet forbindelse av formel I. eller et promedikament, farmasøytisk akseptabelt salt eller solvat av nevnte forbindelse.Videre er foreliggende oppfinnelse rettet mot et farmasøytisk preparat omfattende en farmasøytisk effektiv mengde av en forbindelse av formel I og en farmasøytisk akseptabel bærer.Videre er det beskrevet anvendelse av en forbindelse av formel I som en inhibitor av tryptase, omfattende innføring av forbindelsen i et preparat omfattende tryptase. I tillegg er det beskrevet anvendelse av en forbindelse av formel I for behandling av en pasient som lider av, eller er utsatt for, en fysiologisk tilstand som trenger forbedring av en inhibitor av tryptase som omfatter administrering til pasienten av en terapeutisk effektiv mengde av forbindelsen ifølge krav 1.Det er også beskrevet fremstilling av en forbindelse av formel I.
NO20064811A 2004-03-26 2006-10-23 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase NO20064811L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26
PCT/US2005/009899 WO2005097780A1 (en) 2004-03-26 2005-03-24 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Publications (1)

Publication Number Publication Date
NO20064811L true NO20064811L (no) 2006-10-23

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064811A NO20064811L (no) 2004-03-26 2006-10-23 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase

Country Status (25)

Country Link
US (1) US20070142435A1 (no)
EP (1) EP1737848A1 (no)
JP (1) JP2007530580A (no)
KR (1) KR20060130682A (no)
CN (1) CN1956978A (no)
AR (1) AR048336A1 (no)
AU (1) AU2005230934A1 (no)
BR (1) BRPI0509245A (no)
CA (1) CA2560649A1 (no)
CR (1) CR8603A (no)
DO (1) DOP2005000039A (no)
EC (1) ECSP066878A (no)
IL (1) IL178031A0 (no)
MA (1) MA28547B1 (no)
MX (1) MXPA06010610A (no)
NO (1) NO20064811L (no)
PA (1) PA8627601A1 (no)
PE (1) PE20060084A1 (no)
RU (1) RU2330034C1 (no)
TN (1) TNSN06278A1 (no)
TW (1) TW200602035A (no)
UA (1) UA83738C2 (no)
UY (1) UY28821A1 (no)
WO (1) WO2005097780A1 (no)
ZA (1) ZA200607752B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
WO2008121669A1 (en) * 2007-03-29 2008-10-09 Sanofi-Aventis 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
US8158792B2 (en) 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
CA2713131C (en) * 2008-01-24 2017-01-10 Soligenix, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
CN102149705B (zh) * 2008-08-22 2013-08-07 赛诺菲-安万特 作为肥大细胞类胰蛋白酶抑制剂的[4-(5-氨基甲基-2-氟苯基)-哌啶-1-基]-[7-氟-1-(2-甲氧基乙基)-4-三氟甲氧基-1h-吲哚-3-基]-甲酮
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
MX2012003023A (es) * 2009-09-24 2012-04-10 Sanofi Aventis Us Llc Sintesis del ester terc-butilico del acido (4-fluoro-3-piperidin-4 -il-bencil)-carbamico y sus productos intermedios.
EP2515851A1 (en) * 2009-12-23 2012-10-31 Sanofi Treatment for inflammatory bowel disease
SG181504A1 (en) * 2009-12-23 2012-07-30 Sanofi Sa Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
JP2013515724A (ja) * 2009-12-23 2013-05-09 サノフイ ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類
AU2011220909A1 (en) * 2010-02-24 2012-09-13 Sanofi Treatment of dermatological allergic conditions
EP2763979B1 (en) 2011-10-07 2018-12-26 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
CR20190387A (es) * 2017-02-10 2019-09-25 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
OA12274A (en) * 2000-05-22 2006-05-09 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors.

Also Published As

Publication number Publication date
CN1956978A (zh) 2007-05-02
AR048336A1 (es) 2006-04-19
RU2330034C1 (ru) 2008-07-27
UY28821A1 (es) 2005-10-31
BRPI0509245A (pt) 2007-09-11
PE20060084A1 (es) 2006-03-09
IL178031A0 (en) 2006-12-31
UA83738C2 (en) 2008-08-11
DOP2005000039A (es) 2005-10-31
MXPA06010610A (es) 2006-12-15
EP1737848A1 (en) 2007-01-03
CA2560649A1 (en) 2005-10-20
TNSN06278A1 (en) 2007-12-03
ECSP066878A (es) 2006-11-24
KR20060130682A (ko) 2006-12-19
US20070142435A1 (en) 2007-06-21
AU2005230934A1 (en) 2005-10-20
MA28547B1 (fr) 2007-04-03
JP2007530580A (ja) 2007-11-01
RU2006137717A (ru) 2008-05-10
CR8603A (es) 2007-06-08
WO2005097780A1 (en) 2005-10-20
ZA200607752B (en) 2008-05-28
PA8627601A1 (es) 2006-01-23
TW200602035A (en) 2006-01-16

Similar Documents

Publication Publication Date Title
NO20064811L (no) 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
RU2328283C2 (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20065904L (no) Terapeutiske forbindelser
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
JP2005532372A5 (no)
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MA32639B1 (fr) [4-(5-aminométhyl-2-fluoro-phényl)-pipéridin- 1-yl]-[7-fluoro-1- (2-méthoxy-éthyl)-4-trifluorométhoxy-1h-indol-3-yl]-méthanone en tant qu'inhibiteur de la tryptase de mastocytes
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
DE69927497D1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application